RNA Biosignatures: A Paradigm Change for the Management of Young Febrile Infants

← Back to all studies

RNA Biosignatures: A Paradigm Change for the Management of Young Febrile Infants

Health Categories: Febrile infants / Serious Bacterial Infections (SBIs)
Health Impacts Domain: —

Summary

This study of 2100-2800 infants will refine, validate, and test the clinical utility of RNA biosignatures in practice. Clinicians struggle to differentiate between viral versus bacterial causes for fevers in infants, leading to ineffective or over treatment. RNA bio signatures from a blood sample can distinguish bacterial infections vs. nonbacterial infections.

Key Publications

Related Media

—

Study Details

Long Name
RNA Biosignatures: A Paradigm Change for the Management of Young Febrile Infants
Short Name
Biosig II
Principal Investigator(s)
—
PECARN Node
—

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of the Emergency Medical Services for Children Data Center award totaling $3,200,000 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.